A Message from the CEO

Dear Friends of Glioblastoma Foundation,

As we reflect on the past year, I am filled with immense pride and gratitude for the strides we have made together at the Glioblastoma Foundation. Our mission to transform glioblastoma from a terminal diagnosis into a treatable condition has driven groundbreaking achievements that are reshaping the landscape of glioblastoma research and treatment.

One of our most significant milestones was the opening of the Glioblastoma Foundation Genomic Testing & Research Laboratory in Durham, North Carolina. This state-of-the-art facility will revolutionize glioblastoma care by providing every patient access to advanced genomic testing. By analyzing each tumor’s unique genetic profile, we will enable personalized treatment plans that offer new hope to patients and their families. This laboratory represents a critical step toward our vision of transforming glioblastoma from terminal to treatable.

Additionally, we are proud to announce the acquisition of Lisavanbulin from Basilea Pharmaceutica. This promising drug, which targets microtubules in cancer cells, is now available to three patients in the UK under a post-trial access program. Early results are encouraging, and we are committed to advancing further clinical studies to unlock its full potential for glioblastoma patients.

With your help, we are funding the research that will extend patient survival without compromising quality of life. From support for effective drugs for Glioblastoma, like Osimertinib and Lomustine, to expanding the use of early detection techniques, and other new, innovative programs to advance research from the bench to the bedside, we continue our commitment to transforming glioblastoma therapy.

On a personal note, I was deeply honored to be invited to the CDMRP Stakeholder Meeting for Glioblastoma Research and subsequently asked to join the GBMRP Programmatic Panel. This recognition underscores the Foundation’s growing influence in shaping national research priorities for glioblastoma.

These major accomplishments would not have been possible without your unwavering support. We’re funding the right research that has the highest chance of extending survival for patients. The future is bright for better therapies for glioblastoma. Together, with your help, we can transform glioblastoma from terminal to treatable. Thank you for supporting our mission to fund more effective therapies that work for all patients.

Gita Kwatra, PharmD, MBA
CEO
Glioblastoma Foundation
info@glioblastomafoundation.org